Chase Coleman III
Tiger Global Management
Chase Coleman III Outset MedicalInc stake
total: 436
Tiger Global Management OM trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2020 Q3
- Held for:
- 6 quarters
- Latest activity:
- 2022 Q1
According to 2026 Q2 report, Chase Coleman III doesn't hold any Outset MedicalInc (OM) shares. To date, the estimated cost basis is nearly $750 for "buy" trades and estimated average "sell" price is $691.36. Tiger Global Management first purchased OM in 2020 Q3, initially acquiring 3,667 shares. Since the initial investment in Outset MedicalInc (OM), Tiger Global Management has made 1 more transaction.
When did Chase Coleman III sell Outset MedicalInc (OM)?
Chase Coleman III sold off the entire Outset MedicalInc (OM) position in 2022 Q1.
When did Chase Coleman III buy Outset MedicalInc (OM)?
Chase Coleman III first invested in Outset MedicalInc (OM) in 2020 Q3 at the reported quarter-end price of $750.00 per share.
What's the cost basis of Tiger Global Management's OM stake?
The estimated cost basis for Outset MedicalInc (OM) stake is around $750.00 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $750.00
- Weighted AVG sell price:
- $691.36
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.